Pegylated Liposomal Doxorubicin (Caelyx ® ) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial.
Silvia DellapasquaPamela Trillo AliagaElisabetta MunzoneVincenzo BagnardiEleonora PaganEmilia MontagnaGiuseppe CancelloRaffaella GhisiniClaudia SangalliMara NegriManuelita MazzaMonica IorfidaAnna CardilloAngela SciandivasciNadia BiancoAna Paula De MaioMonica MilanoGiuseppe Maria CampennìLoredana SansonnoGiuseppe VialeAnna MorraMaria Cristina LeonardiViviana GalimbertiPaolo VeronesiMarco ColleoniPublished in: Current oncology (Toronto, Ont.) (2021)
The trial successfully met its primary endpoint: the regimen was feasible and well tolerated and could be considered for further evaluation as a treatment option for patients with contraindications to standard anthracyclines or requiring a personalized, less intensive approach.